Navigation Links
Veridex Announces Agreement to Acquire the Assets of Immunicon Corporation
Date:6/11/2008

RARITAN, N.J., June 11 /PRNewswire-FirstCall/ -- Veridex, LLC announced today that it has signed an asset purchase agreement to acquire substantially all of the assets of Immunicon Corporation (OTC Bulletin Board: IMMC) for $31 million in cash subject to certain closing date adjustments, plus the discharge and release of certain claims owing to Veridex, LLC and the assumption of certain specified liabilities.

The assets to be acquired include intellectual property, product inventory and clinical data as well as all technologies related to the CellSearch(TM) System, the first diagnostic test to automate the detection and enumeration of circulating tumor cells (CTCs), cancer cells that detach from solid tumors and enter the blood stream. The CellSearch(TM) System is currently cleared for the prognosis and monitoring of patients with metastatic breast, metastatic colorectal and metastatic prostate cancer.

"This agreement represents a strategic opportunity for Veridex to continue to bring innovative diagnostic tests to the patients, physicians and laboratories involved in the fight against cancer," said Ken Berlin, General Manager, Veridex, LLC.

Veridex and Immunicon have partnered since 2000 to develop and commercialize novel cancer diagnostic platforms and products.

The transaction is subject to the approval by the bankruptcy court overseeing Immunicon's bankruptcy case. It is not expected to require anti-trust review or shareholder approval.

About Veridex

Veridex, LLC, a Johnson & Johnson company, is an organization dedicated to providing physicians with high-value in vitro diagnostic oncology products. Veridex is focused on developing products that will significantly benefit patients through earlier disease detection, and enable personalized medicine strategies to improve patient management and outcomes. The company develops cancer diagnostic products that may enable earlier disease detection as well as more accurate monitoring and therapeutic selection. The company is currently marketing two product lines: CellSearch(TM) assays that enumerate circulating tumor cells in blood and GeneSearch(TM) assays using molecular technology. For additional information, please visit http://www.veridex.com

(This press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could vary materially from Veridex's expectations and projections. Risks and uncertainties include the satisfaction of closing conditions for the acquisition, including receipt of approval for the transaction by the bankruptcy court overseeing Immunicon's bankruptcy case, and the possibility that the transaction will not be completed; general industry conditions and competition; economic conditions, such as interest rate and currency exchange rate fluctuations; technological advances and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approvals; domestic and foreign health care reforms and governmental laws and regulations; and trends toward health care cost containment. A further list and description of these risks, uncertainties and other factors can be found in Exhibit 99 of Johnson & Johnson's Annual Report on Form 10-K for the fiscal year ended December 30, 2007. Copies of this Form 10-K, as well as subsequent filings, are available online at http://www.sec.gov, http://www.jnj.com or on request from Johnson & Johnson. Veridex does not undertake to update any forward-looking statements as a result of new information or future events or developments.)


'/>"/>
SOURCE Veridex, LLC
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. BioSpecifics Technologies Corp. Announces Additional Sales of Stock in Private Placement Offering
2. Diffusion Pharmaceuticals Announces Addition of Mark T. Giles to its Board of Directors
3. Oncolytics Biotech Inc. Announces Start of Enrolment in Phase 1/2 Ovarian Cancer Clinical Trial with REOLYSIN(R)
4. Appature Announces onKey as an Innovative Platform for Creating Microsoft HealthVault-Compatible Applications
5. Premier Research Announces Completion of Management Buyout
6. ProMetic announces Octapharma publication of PRDTS prion removal resin in Octaplas(R) manufacturing process at 30th International Congress of the International Society for Blood Transfusion meeting in Macao SAR, China
7. Nuevolution Announces Drug Discovery Alliance With Lexicon Pharmaceuticals
8. onTargetjobs Announces Appointment of Michael Tansey as New CEO
9. Tethys Bioscience Announces Expanded Availability of PreDx(TM) Diabetes Risk Test
10. QLT announces positive Health Canada decision on Aczone(R)
11. ETHICON, INC. Announces Revised Label For REGRANEX(R) (becaplermin) Gel 0.01%
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... ... ... Disappearing forests and increased emissions are the main causes of the evolving air ... living in larger cities are affected by air pollution related diseases. , That is ... globally - decided to take action. , “I knew I had to take action ...
(Date:10/10/2017)... DIEGO, CALIF. (PRWEB) , ... October 10, 2017 , ... ... as part of its corporate rebranding initiative announced today. The bold new look ... its reach, as the company moves into a significant growth period. , It will ...
(Date:10/10/2017)... ... 2017 , ... Dr. Bob Harman, founder and CEO of VetStem Biopharma, ... The event entitled “Stem Cells and Their Regenerative Powers,” was held on ... DVM, MPVM was joined by two human doctors: Peter B. Hanson, M.D., Chief of ...
(Date:10/10/2017)... ... 10, 2017 , ... USDM Life Sciences , the ... sciences and healthcare industries, announces a presentation by Subbu Viswanathan and Jennifer Jaye ... GxP Validation for Agile Cloud Platforms,” will present a revolutionary approach to achieving ...
Breaking Biology Technology:
(Date:5/16/2017)... --  Bridge Patient Portal , an enterprise patient ... Systems , an electronic medical record solutions developer ... a partnership to build an interface between the ... products, including Centricity Practice Solution (CPS), Centricity Business ... integrations will allow healthcare delivery networks using GE ...
(Date:4/24/2017)... Janice Kephart , former 9/11 ... Partners, LLP (IdSP) , today issues the following ... March 6, 2017 Executive Order: Protecting the ... be instilled with greater confidence, enabling the reactivation ... applications are suspended by until at least July ...
(Date:4/18/2017)... Inc., a global expert in SoC-based imaging and computing solutions, has ... features the company,s hybrid codec technology. A demonstration utilizing TeraFaces ® ... be showcased during the upcoming Medtec Japan at Tokyo Big Sight ... Las Vegas Convention Center April 24-27. ... Click here for an image of the ...
Breaking Biology News(10 mins):